Evidence map›Paper›PMID 34857845›Full record

ArticleScientific reports2021

Analysis of site and structure specific core fucosylation in liver cirrhosis using exoglycosidase-assisted data-independent LC-MS/MS.

Miloslav Sanda, Jaeil Ahn, Petr Kozlik, Radoslav Goldman

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. An insight on theFASEB bioAdvances · 2023
    Article
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Miloslav SandaDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, 20057, USA. ms2465@georgetown.edu.
Jaeil AhnDepartment of Biostatistics, Bioinformatics and Biomathematics, Georgetown University Medical Center, Washington, DC, 20057, USA.
Petr KozlikDepartment of Analytical Chemistry, Faculty of Science, Charles University, Prague, Czech Republic.
Radoslav GoldmanDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, 20057, USA.
Georgetown University · USCharles University · CZGeorgetown University Medical Center · US

Funding

Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI Louis M Weiner · 1990 to 2026
$71.5M
Glycans in Hepatocellular CarcinomaR01CA135069 · NCI · GEORGETOWN UNIVERSITY · PI GOLDMAN, RADOSLAV · 2009 to 2019
$4.1M
O-glycoproteins in the progression of liver diseaseR01CA238455 · NCI · GEORGETOWN UNIVERSITY · PI GOLDMAN, RADOSLAV · 2019 to 2023
$2.6M
LC-MS Analysis of Site Specific Protein GlycoformsU01CA230692 · NCI · GEORGETOWN UNIVERSITY · PI EDWARDS, NATHAN J, GOLDMAN, RADOSLAV · 2018 to 2020
$1.3M
Orbitrap Fusion Lumos ETDS10OD023557 · OD · GEORGETOWN UNIVERSITY · PI GOLDMAN, RADOSLAV · 2017 to 2017
$1.1M
NCI NIH HHS P30 CA051008NCI NIH HHS R01 CA135069NCI NIH HHS R01 CA238455NCI NIH HHS U01 CA230692NIH HHS S10 OD023557
6 · The paper itself

Abstract

Carbohydrates form one of the major groups of biological macromolecules in living organisms. Many biological processes including protein folding, stability, immune response, and receptor activation are regulated by glycosylation. Fucosylation of proteins regulates such processes and is associated with various diseases including autoimmunity and cancer. Mass spectrometry efficiently identifies structures of fucosylated glycans or sites of core fucosylated N-glycopeptides but quantification of the glycopeptides remains less explored. We performed experiments that facilitate quantitative analysis of the core fucosylation of proteins with partial structural resolution of the glycans and we present results of the mass spectrometric SWATH-type DIA analysis of relative abundances of the core fucosylated glycoforms of 45 glycopeptides to their nonfucosylated glycoforms derived from 18 serum proteins in liver disease of different etiologies. Our results show that a combination of soft fragmentation with exoglycosidases is efficient at the assignment and quantification of the core fucosylated N-glycoforms at specific sites of protein attachment. In addition, our results show that disease-associated changes in core fucosylation are peptide-dependent and further differ by branching of the core fucosylated glycans. Further studies are needed to verify whether tri- and tetra-antennary core fucosylated glycopeptides could be used as markers of liver disease progression.

Indexed as

Glycoside HydrolasesBiomarkersChromatography, LiquidFucoseGlycopeptidesGlycosylationHumansLiver CirrhosisPolysaccharidesTandem Mass SpectrometryBiomarkersFucoseGlycopeptidesGlycoside HydrolasesPolysaccharides

Identifiers

PMID34857845
PMCPMC8639754
OpenAlexW3216633138

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.